The CRTC-CREB Axis as a Conserved Sensor of Proteotoxic Stress

Study Background and Research Question

Proteotoxic stress, characterized by the accumulation of misfolded or aggregated proteins, is a central feature of many neurodegenerative diseases such as Huntington’s disease. The cellular capacity to sense and respond to such stress is critical for maintaining proteostasis and promoting organismal health, especially during aging. Transcription factors like cAMP Responsive Element Binding Protein (CREB) play pivotal roles in regulating cellular responses to metabolic and developmental stimuli, with activation modulated by upstream kinases and coactivators such as CRTC (CREB Regulated Transcriptional Coactivator). However, the precise mechanisms by which the CRTC-CREB axis detects and orchestrates defenses against proteotoxic stress in live organisms have remained unclear. The recent study in Drosophila addresses this gap by probing how CREB activity is regulated by proteasome inhibition and the downstream signaling events that influence cellular resilience to protein aggregation.

Key Innovation from the Reference Study

The central innovation of this study lies in demonstrating that the CRTC-CREB axis functions as a transcriptional sensor for proteotoxic stress in vivo, with a mechanistic link established between proteasome inhibition, reactive oxygen species (ROS) generation, JNK signaling, and CREB activation. Notably, the authors leveraged a large-scale compound screening approach—enabled by overcoming technical barriers to drug delivery in adult flies—to identify FDA-approved proteasome inhibitors as potent activators of CREB. This work not only maps a conserved stress-responsive pathway but also suggests new therapeutic avenues for protein aggregation diseases by modulating the CRTC-CREB axis.

Methods and Experimental Design Insights

The study utilized adult Drosophila as a model system, introducing a sustainable and efficient U-GLAD (U shape Gum Arabic Liquid Assisted Drug delivery system) to facilitate large-scale compound screening in vivo, overcoming previous solubility and delivery challenges. The research team screened compounds from FDA-approved drug libraries, including proteasome inhibitors such as MLN2238, to monitor CREB activity. CREB activation was tracked using reporter assays, and key pathway dependencies were dissected through genetic and pharmacological manipulations. In parallel, transcriptomic profiling of fly intestines following CRTC overexpression elucidated downstream gene networks involved in redox and proteostatic regulation. The functional impact of CRTC-CREB activation was then evaluated in a Drosophila Huntington’s disease model, assessing phenotypes such as protein aggregation, motility, and lifespan.

Protocol Parameters

• Compound screening: Use pre-dissolved, high-purity FDA-approved compounds suitable for in vivo delivery; apply U-GLAD or comparable systems for adult fly administration.
• CREB activity assays: Employ CRE-luciferase or GFP reporter lines; measure luminescence/fluorescence following compound exposure (e.g., 24–48 hours post-treatment).
• Genetic manipulations: Overexpress or knockdown CRTC/CREB in tissue-specific patterns (e.g., muscle or intestine) using Gal4/UAS system.
• ROS/JNK pathway interrogation: Apply JNK pathway inhibitors or use mutants to confirm pathway involvement; assess CREB phosphorylation and downstream transcriptional responses.
• Proteotoxic stress modeling: Induce protein aggregation genetically (e.g., polyQ-expanded huntingtin expression) or via pharmacological proteasome inhibition.
• Phenotypic assays: Quantify protein aggregates (immunofluorescence), motility (climbing assays), and survival/lifespan in treated and control cohorts.
• Transcriptomic analysis: Perform RNA-seq on targeted tissues to identify differentially expressed genes upon CRTC overexpression or stress induction.

Core Findings and Why They Matter

The study’s major findings can be summarized as follows:

• Proteasome inhibitors from FDA-approved compound libraries robustly activate CREB in adult Drosophila, with the effect confirmed in both fly and mammalian cells (reference).
• This activation is mediated by ROS generated during proteasome inhibition, which triggers JNK signaling. JNK, in turn, increases CREB phosphorylation (notably at Ser133 in mammals and the analogous Ser231 in flies), boosting its transcriptional activity.
• Transcriptome analysis reveals that CRTC overexpression upregulates genes involved in redox homeostasis and protein folding/degradation, highlighting a direct transcriptional program for proteostatic defense.
• In a Drosophila Huntington’s disease model, muscle-specific CRTC overexpression restores proteasomal function, reduces toxic protein aggregates, improves motility, and extends lifespan—demonstrating functional rescue of neurodegenerative phenotypes.
• CREB activity naturally increases with age, and further enhancement of this pathway suppresses age-related protein aggregation in muscle tissues.

These discoveries establish the CRTC-CREB axis as a conserved, inducible sensor and effector of cellular defense against proteotoxic and oxidative stresses. The mechanistic clarity provided by this study opens the door for targeted pharmacological interventions in neurodegenerative and age-associated proteinopathies. Importantly, the functional rescue seen in fly disease models provides a compelling proof-of-concept for therapeutic strategies aimed at modulating this axis.

Comparison with Existing Internal Articles

Several recent resources have explored the utility of FDA-approved bioactive compound libraries in translational research. For example, the article "Advanced Strategies for Protein Misfolding Disease Screening" discusses how libraries like the DiscoveryProbe FDA-approved Drug Library facilitate high-throughput screening and target identification in protein aggregation disorders. This aligns with the reference study’s approach, where curated libraries enabled unbiased discovery of proteasome inhibitors as CREB activators. In addition, the "Accelerating Target Discovery in Neurodegeneration" article highlights the value of ready-to-use, stable compound collections for drug repositioning in neurodegenerative models, echoing the screening strategy and translational aims of the Drosophila work.

These internal articles provide practical guidance on leveraging comprehensive FDA-approved compound libraries for pharmacological target identification and drug repositioning screening, reinforcing the workflow demonstrated in the reference study. Notably, the streamlined delivery and screening methodologies described internally are mirrored by the reference paper’s adoption of the U-GLAD system and cross-species validation.

Limitations and Transferability

While the findings in Drosophila provide robust evidence for the role of the CRTC-CREB axis in proteostatic stress response, several limitations should be considered:

• Species differences: Although CREB signaling is conserved, detailed mechanistic differences exist between flies and mammals, such as phosphorylation site usage and regulatory co-factors.
• Drug delivery: The U-GLAD system is optimized for Drosophila; adaptation to mammalian in vivo models may require alternative delivery strategies.
• Complexity of human neurodegenerative disease: Human diseases like Huntington’s involve multifactorial pathologies, so translation of single-pathway interventions requires further validation in mammalian and clinical models.
• Library coverage: While the screening covered FDA-approved proteasome inhibitors, the full diversity of mechanisms influencing CREB in vivo remains to be systematically explored.

Despite these caveats, the core mechanistic insights—particularly the stress-induced ROS/JNK/CREB regulatory circuit—are broadly relevant for pharmacological target identification in protein misfolding and aggregation contexts.

Why this cross-domain matters, maturity, and limitations

The bridge established by this study—from basic proteostasis mechanisms in flies to translational neurodegeneration research—demonstrates the value of model organisms and unbiased compound screening for uncovering conserved therapeutic targets. However, the maturity of these findings for direct clinical translation is limited by species-specific variables and the need for validation in mammalian systems and human tissues.

Research Support Resources

Researchers aiming to replicate or extend these workflows can benefit from curated, ready-to-use compound libraries. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a resource designed to support high-throughput screening and drug repositioning in diverse biomedical models, including neurodegenerative disease drug discovery and cancer research drug screening. This FDA-approved bioactive compound library provides pre-dissolved, quality-controlled compounds suitable for in vivo and in vitro screening, paralleling the methodology described in the reference study. Further technical and workflow guidance is available in recent internal articles, including scenario-based Q&A and protocol optimization advice.